{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cough-acute-with-chest-signs-in-children/prescribing-information/macrolides/","result":{"pageContext":{"chapter":{"id":"87a5f8d7-3f8e-5b8e-81b4-364a14a73467","slug":"macrolides","fullItemName":"Macrolides","depth":2,"htmlHeader":"<!-- begin field 68eb3636-4361-4a3b-88f6-a70100f5d637 --><h2>Macrolides</h2><!-- end field 68eb3636-4361-4a3b-88f6-a70100f5d637 -->","summary":"","htmlStringContent":"<!-- begin item af39ba09-85ea-466d-bcb7-a70100f5d237 --><!-- end item af39ba09-85ea-466d-bcb7-a70100f5d237 -->","topic":{"id":"ecc57759-d8a2-50b5-addc-68127dd57e13","topicId":"6f239a86-8a9f-4fc1-85b2-df045fbf9477","topicName":"Cough - acute with chest signs in children","slug":"cough-acute-with-chest-signs-in-children","lastRevised":"Last revised in January 2021","chapters":[{"id":"82620eeb-35c8-583d-957c-c8c9d68f0bc4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"85e154c6-7444-55c1-8105-4238c565d6d6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"34d842b6-5846-5142-96f5-6451b7b9503f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"94ebcc3a-8e44-5c7a-84a1-44c122e86fc5","slug":"changes","fullItemName":"Changes"},{"id":"19991281-8b30-5f16-8552-ba71a6c2257f","slug":"update","fullItemName":"Update"}]},{"id":"31245ad9-f63e-5053-8f0f-9e310f133212","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b1846e94-64be-5a1d-b26e-9bc518192b43","slug":"goals","fullItemName":"Goals"},{"id":"52d51fe3-1e3c-5479-82e5-628353de2bda","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"59199121-d653-59c9-a7ff-03835d711500","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"73cf3120-d25a-5284-8593-e93c81d39c8d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4f7d288f-bf0c-5dd9-aad8-54ef82e7e039","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"60fdd9e2-e6fd-5e5b-98d4-33afb2271bf6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"40cbe9e5-667a-56f8-9039-e094f48e40da","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b9756443-edc1-5707-af00-970491b93f52","slug":"definition","fullItemName":"Definition"},{"id":"ef20d952-44e6-5372-8021-cb07f3444dc1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"39f5f767-cf1c-554f-ac8c-1c89c7b73a53","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"eee4bb33-4743-5ff3-b4e0-221f6f6670c7","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"476813be-e2a1-5849-b379-e674dda72f03","slug":"diagnosis-of-cause","fullItemName":"Diagnosis of cause"},{"id":"b9d5f16f-3395-562d-a46b-b1f06bd6bed5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"899fa269-48ce-5ff0-82b9-83b8bbd23fd5","fullItemName":"Management","slug":"management","subChapters":[{"id":"a34c98a9-afaf-51ce-9449-23569af98723","slug":"viral-induced-wheeze-possible-asthma","fullItemName":"Scenario: Viral-induced wheeze/possible asthma"},{"id":"87edfa6f-d156-5750-9778-a82799c16245","slug":"bronchiolitis","fullItemName":"Scenario: Bronchiolitis"},{"id":"aa61e13e-692a-56aa-a17b-a9429aa076d0","slug":"community-acquired-pneumonia","fullItemName":"Scenario: Community-acquired pneumonia"}]},{"id":"e3645b31-0302-5b3c-ad3d-fad31e7f02f9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f1a05b5b-c5fe-5138-a544-4d447c78a07e","slug":"amoxicillin-co-amoxiclav","fullItemName":"Amoxicillin and co-amoxiclav"},{"id":"82dc91ea-2a15-5ea8-979f-6ff8f0d34a7a","slug":"cefaclor","fullItemName":"Cefaclor"},{"id":"64d06ec1-7d56-574c-a9cc-ee35cfd204e4","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"20c13e81-9ef3-5df6-9f51-eb0dfacaaeab","slug":"ibuprofen-paracetamol","fullItemName":"Ibuprofen and paracetamol"},{"id":"87a5f8d7-3f8e-5b8e-81b4-364a14a73467","slug":"macrolides","fullItemName":"Macrolides"},{"id":"0697a2ca-e9c2-512d-ab11-d573f39abddf","slug":"prednisolone","fullItemName":"Prednisolone"},{"id":"f40afbec-15db-5ba5-8bf8-b4ddeee5aeec","slug":"short-acting-beta-2-agonists","fullItemName":"Short-acting beta-2 agonists"}]},{"id":"91f18501-a585-5063-808d-45ce72bc128b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"87a7a774-5455-587b-b324-53fd94fb5173","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0ddbcc1e-d9b8-5a7f-becd-f71b188dbbd0","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d35bce52-adec-5cb7-9ea1-acf95169edd6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a68992e4-ba15-5c95-9370-e987b9a61f0e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"610e5926-a430-5217-a4dc-6de7f4a3d7c8","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d9335bd0-caf6-5162-a6c3-4efb35bf6011","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b3e96fe7-7269-59f4-8328-c9710f4dbc76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e3645b31-0302-5b3c-ad3d-fad31e7f02f9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"97b3f361-9acc-53b9-a3fd-d40abba601b3","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 99c29307-2909-440f-ab66-a70100fb9712 --><h3>Contraindications and cautions</h3><!-- end field 99c29307-2909-440f-ab66-a70100fb9712 -->","summary":"","htmlStringContent":"<!-- begin item 926ede3e-f502-4a1e-8747-a70100fb9354 --><!-- begin field ed8f0a7b-c772-459a-8ba4-a70100fb9712 --><h4>Clarithromycin</h4><ul><li><strong>Do not prescribe clarithromycin to people:</strong><ul><li>With severe hepatic impairment in combination with renal impairment.</li><li>Taking drugs that prolong the QT interval (for example haloperidol, sotalol, amisulpride, terfenadine, and pimozide) — macrolides can also prolong the QT interval, which is a risk factor for Torsades de pointes.</li><li>With hypokalaemia — due to the risk of prolongation of the QT interval.</li><li>With a history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de pointes.</li></ul></li><li><strong>Prescribe clarithromycin with caution to people with:</strong><ul><li>Hepatic impairment (or people concomitantly receiving potentially hepatotoxic drugs) — clarithromycin is mainly excreted by the liver.</li><li>Moderate to severe renal impairment.<ul><li>Use half the normal dose in severe renal impairment (eGFR less than 30 mL/min). Avoid Klaricid XL<sup>® </sup>(clarithromycin prolonged-release once daily tablets) in people with eGFR less than 30 mL/min, as the dose cannot be reduced.</li></ul></li><li>Myasthenia gravis — macrolides may aggravate weakness symptoms.</li><li>Severe cardiac insufficiency, or bradycardia (less than 50 beats per minute) — increased risk of QT prolongation.</li></ul></li></ul><h4>Erythromycin</h4><ul><li><strong>Do not prescribe erythromycin to people with </strong><ul><li>Porphyria.</li><li>A history of QT interval prolongation or ventricular cardiac arrhythmia.</li><li>Conditions that predispose to QT interval prolongation such as electrolyte disturbances and people taking drugs that prolong the QT interval.</li></ul></li><li><strong>Prescribe erythromycin with caution to people with:</strong></li><li>neonate under 2 weeks (risk of hypertrophic pyloric stenosis)<ul><li>Hepatic impairment (or people concomitantly receiving potentially hepatotoxic drugs) — erythromycin is mainly excreted by the liver.</li><li>Taking drugs that prolong the QT interval (for example haloperidol, sotalol, amisulpride, terfenadine [avoid use with terfenadine], and pimozide) — macrolides can also prolong the QT interval, which is a risk factor for Torsades de pointes.</li><li>Moderate to severe renal impairment:<ul><li>Give a maximum dose for erythromycin of 1.5 g a day in severe renal impairment due to the risk of ototoxicity.</li></ul></li><li>Myasthenia gravis — macrolides may aggravate weakness symptoms.</li><li>Conditions that predispose to QT interval prolongation.</li></ul></li></ul><h4>Azithromycin</h4><ul><li><strong>Do not prescribe azithromycin to people:</strong><ul><li>With severe hepatic impairment.</li><li>Taking drugs that prolong the QT interval (for example haloperidol, sotalol, amisulpride, terfenadine, and pimozide) — macrolides can also prolong the QT interval, which is a risk factor for Torsades de pointes.</li><li>With hypokalaemia, due to the risk of prolongation of the QT interval.</li><li>With a history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de pointes.</li></ul></li><li><strong>Prescribe azithromycin with caution to people with:</strong><ul><li>Mild to moderate hepatic impairment.</li><li>Moderate to severe renal impairment.</li><li>Myasthenia gravis — macrolides may aggravate weakness symptoms.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">ABPI Medicines Compendium, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">MHRA, 2020</a>]</p><!-- end field ed8f0a7b-c772-459a-8ba4-a70100fb9712 --><!-- end item 926ede3e-f502-4a1e-8747-a70100fb9354 -->","subChapters":[]},{"id":"b9916520-8702-5493-aa05-9ff023bab08f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field b66eda8d-2031-43b1-9a84-a70100fbaddd --><h3>Adverse effects</h3><!-- end field b66eda8d-2031-43b1-9a84-a70100fbaddd -->","summary":"","htmlStringContent":"<!-- begin item 93dbca41-9b2c-4700-b3ab-a70100fbaabe --><!-- begin field 188567aa-a3d9-4e14-ad93-a70100fbaddd --><ul><li><strong>Nausea, vomiting, abdominal discomfort, and diarrhoea </strong>are the most common adverse effects of macrolides, and are milder and less frequent with clarithromycin and azithromycin than with erythromycin.</li><li><strong>Consider pseudomembranous colitis </strong>if a person develops severe diarrhoea during or after treatment with a macrolide.<ul><li>Pseudomembranous colitis is an acute, exudative colitis caused by <em>Clostridium difficile</em>, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Anaphylaxis </strong>is rarely associated with macrolide treatment.</li><li><strong>Hepatotoxicity (including cholestatic jaundice) and rash </strong>have been reported following treatment with macrolides.</li><li><strong>Reversible hearing loss (sometimes with tinnitus) </strong>can occur after large doses of clarithromycin (1–2 g) and erythromycin (4 g).</li><li><strong>Other adverse effects reported rarely or very rarely include </strong>pancreatitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">ABPI Medicines Compendium, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">BNF 72, 2016</a>]</p><!-- end field 188567aa-a3d9-4e14-ad93-a70100fbaddd --><!-- end item 93dbca41-9b2c-4700-b3ab-a70100fbaabe -->","subChapters":[]},{"id":"6ecfdc46-290f-5a3a-bbb8-783cd459da04","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 39c83fc7-e94a-4fb3-ade6-a70100fbcdbc --><h3>Drug interactions</h3><!-- end field 39c83fc7-e94a-4fb3-ade6-a70100fbcdbc -->","summary":"","htmlStringContent":"<!-- begin item d23d6f48-d0ef-4ed1-a6e9-a70100fbc944 --><!-- begin field a2de40e9-2528-438d-b1a1-a70100fbcdbc --><p><strong>Drug interactions with macrolides include:</strong></p><ul><li><strong>Carbamazepine </strong>— macrolides inhibit the cytochrome P450 enzyme CYP3A4, resulting in reduced carbamazepine metabolism.<ul><li>Reduce the dose of carbamazepine by 30–50% during treatment with macrolides.</li><li>Advise the person to report symptoms of carbamazepine toxicity (such as dizziness, diplopia, ataxia, or confusion).</li></ul></li><li><strong>Rivaroxaban </strong>— erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Warfarin </strong>— occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Calcium channel blockers (CCB's) </strong>— due to an increased risk of hypotension, caution is advised with the concurrent use of macrolides and CCB's metabolised by CYP3A4 (such as verapamil, amlodipine, and diltiazem).</li><li><strong>Drugs that prolong the QT interval </strong>(such as haloperidol, sotalol, terfenadine, and pimozide) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Drugs that cause hypokalaemia </strong>(such as diuretics, corticosteroids, short-acting beta<sub>2</sub>-agonists) — hypokalaemia is a risk factor for QT prolongation.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Ciclosporin </strong>— azithromycin can affect clearance of ciclosporin. If co-administration of these drugs is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.</li><li><strong>Oral hypoglycaemic drugs and insulin </strong>— the concomitant use of clarithromycin and oral hypoglycaemic drugs (such as sulphonylureas) and/or insulin can result in significant hypoglycaemia. Careful monitoring of glucose levels is recommended.</li><li><strong>Theophylline </strong>— erythromycin increases plasma concentrations of theophylline, and theophylline may also reduce absorption of oral erythromycin.<ul><li>Check theophylline levels 48 hours after starting erythromycin, and adjust the dose of theophylline accordingly.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">ABPI Medicines Compendium, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">MHRA, 2020</a>]</p><!-- end field a2de40e9-2528-438d-b1a1-a70100fbcdbc --><!-- end item d23d6f48-d0ef-4ed1-a6e9-a70100fbc944 -->","subChapters":[]},{"id":"c87ae4a3-a6a1-5105-89f4-383093fb8a82","slug":"dosing-information","fullItemName":"Dosing information","depth":3,"htmlHeader":"<!-- begin field 5a415e23-b0b3-49b3-b8d4-a70100fbfac7 --><h3>Dose</h3><!-- end field 5a415e23-b0b3-49b3-b8d4-a70100fbfac7 -->","summary":"","htmlStringContent":"<!-- begin item f705cd22-f64b-4334-b0c4-a70100fbf7ec --><!-- begin field cc266c8c-a907-4543-a79c-a70100fbfac7 --><h4>Clarithromycin</h4><ul><li>Body weight under 8 kg: 7.5 mg/kg twice a day.</li><li>Body weight 8–11 kg: 62.5 mg twice a day.</li><li>Body weight 12–19 kg: 125 mg twice a day.</li><li>Body weight 20–29 kg: 187.5 mg twice a day.</li><li>Body weight 30–40 kg: 250 mg twice a day.</li><li>Child 12–16 years: 250 mg twice daily, increased if necessary in severe infections to 500 mg twice a day.</li></ul><h4>Erythromycin</h4><ul><li outputclass=\"neonate\">Neonate: 3 mg/kg 4 times daily.</li><li>Child 1 month –16 years: 3 mg/kg 4 times daily</li></ul><h4>Azithromycin</h4><ul><li>Child over 6 months: 10 mg/kg once daily (max. 500 mg once daily), <em>or</em></li><li>Body-weight 15–25 kg: 200 mg once daily.</li><li>Body-weight 26–35 kg: 300 mg once daily.</li><li>Body-weight 36–45 kg: 400 mg once daily.</li><li>Body-weight over 45 kg: 500 mg once daily.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">BNF 72, 2016</a>]</p><!-- end field cc266c8c-a907-4543-a79c-a70100fbfac7 --><!-- end item f705cd22-f64b-4334-b0c4-a70100fbf7ec -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}